Back to results
US 7,923,538 B2Granted
Recombinant antibody composition
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsKenya Shitara, Rinpei Niwa, Akito Natsume
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsKenya Shitara, Rinpei Niwa, Akito Natsume
Estimating the term…
The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
A recombinant version of an antibody capable of specifically binding an antigen, said recombinant version comprising the light chain of the antibody and a recombinant heavy chain comprising the heavy chain variable domain of the antibody and a heterologous heavy chain constant domain comprising the amino acid sequence of SEQ ID NO:50, wherein said recombinant version retains the binding specificity of said antibody.
Dependencies are inferred from the claim text.